Compare Heron Therapeutics Inc (HRTX) vs Kohl's Corporation (KSS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Kohl's Corporation — how do they compare? Heron Therapeutics Inc trades at $0.41 (market cap $68.01M), while Kohl's Corporation trades at $20.31 (market cap $2.28B). The key difference: Kohl's Corporation is far larger — about 33.5× Heron Therapeutics Inc's market cap, and Kohl's Corporation pays a 2.49% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Kohl's Corporation for 48 Days on average.
| HRTX | KSS | |
|---|---|---|
Market Cap | $68.01M | $2.28B |
Volume | 1,891,941 | 4,960,280 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.49 | $24.71 |
52-Week Low | $0.27 | $11.72 |
Typical Hold Time | 35 Days | 48 Days |
Enterprise Value | $174.75M | $7.88B |
Dividend Yield | — | 2.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.39, up 0.95% with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics, analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings discussions.
The outlook remains challenged by persistent losses and negative margins, though strong analyst support suggests potential upside. Key risks include execution on sales targets and achieving profitability. The stock's low price near 52-week lows presents speculative opportunity but requires careful risk management given financial performance.
Kohl's (KSS) trades at $20.12, up 2.5% today, with a bullish technical signal driven by moving averages but overbought RSI readings. The stock shows deep value with a P/E of 8.63 and P/B of 0.55, though revenue has declined annually since 2022. Recent Q2 2026 earnings beat estimates with EPS of $1.28, and the company raised full-year guidance, supported by margin gains and a new chief merchandising officer appointment.
The outlook is mixed: low valuation and earnings momentum offer upside, but persistent sales declines and competitive pressures pose risks. Analyst consensus is cautious with a $15.50 price target below the current price, reflecting skepticism about the sustainability of the turnaround amid consumer spending shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →
